EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Utility of PROSTest: A Prospective Study Suggesting Reduction in Unnecessary MRI and Biopsy in Men Evaluated for Prostate Cancer

Kambiz Rahbar iD, Martin Bögemann iD, Philipp Papavasilis, Abdel Halim, Mark Kidd iD

Cancers · 08.03.2026 · 18 (5) · 871

DOI: 10.3390/cancers18050871 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 08.03.2026. Verfasst von Kambiz Rahbar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University Hospital Muenster, 48149 Muenster, Germany. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Early detection of prostate cancer (PCa) enables timely therapeutic intervention and improved clinical outcomes. Screening strategies are increasingly individualized and now incorporate multiparametric MRI findings, reported using the Prostate Imaging Reporting and Data System (PI-RADS), to refine biopsy decision-making. PROSTest is a novel machine learning (ML)-enhanced, 30-gene mRNA liquid biopsy assay developed to detect PCa from whole blood. In this prospective study (NCT06872619), we evaluated whether PROSTest could function as a pre-biopsy triage tool to inform biopsy decisions while preserving sensitivity for clinically significant prostate cancer (csPCa).

Methods

Of 121 men evaluated, 111 (91.7%) completed the full diagnostic work-up—including PSA testing, PROSTest analysis, and PI-RADS assessment—and subsequently underwent image-guided biopsy. Peripheral blood samples for PROSTest were collected prior to biopsy. RNA-stabilized samples underwent RNA isolation followed by reverse transcription and quantitative PCR. Gene expression data were processed using a proprietary machine learning algorithm to generate a continuous range from 0 to 100. A clinically validated cut-off ≥ 50 was applied to produce a binary (positive/negative) result. The diagnostic accuracy of PROSTest was assessed against histology-confirmed prostate cancer.

Results

The median age of participants was 69 years (47–83 years) and the median PSA was 7.5 ng/mL (IQR: 5.8–11.4 ng/mL); most patients (104 of 111; 93.7%) had a PI-RADS score of three to five. PCa was diagnosed in 97 men (87.4%) including eight in ISUP Grade Group (GG) 1, 46 in GG2, 33 in GG3, three in GG4 and seven in GG5. PROSTest was positive in 102/111 (91.9%). Among men with biopsy-confirmed PCa, diagnostic accuracy was 99% (93/94). Of the 17 men without histologic evidence of disease, eight (47%) were PROSTest-negative. The overall accuracy was 91% (84.1–95.6%) with an NPV of 89% (51.6–98.4%). Among the nine patients with positive PROSTest but negative biopsy, PI-RADS scores were 4 (n = 6), 3 (n = 1), and 2 (n = 2).

Conclusions

PROSTest demonstrated an overall accuracy of 91% (95% CI: 84.1–95.6%) with an NPV of 89%. Among men without a detectable prostate cancer on biopsy, 47% (8/17) were PROSTest-negative. These results suggest that PROSTest may serve as a useful pre-biopsy triage assay.

Schlagwörter

Stichwörter der Autor:innen

MRIPCRPROSTestPSAgene expressionliquid biopsyprostate cancer screening

Autor:innen und Institutionen

  • Department of Nuclear Medicine, University Hospital Muenster, 48149 Muenster, Germany.
  • West German Cancer Centre Muenster (WTZ), 48149 Muenster, Germany.
  • Department of Urology, University Hospital Muenster, 48149 Muenster, Germany.
  • Wren Laboratories, Branford, CT 06405, USA.

ORCID-Profile: Kambiz Rahbar, Martin Bögemann, Mark Kidd

Zitieren

APA

Rahbar, K., Bögemann, M., Papavasilis, P., Halim, A., & Kidd, M. (2026). Clinical Utility of PROSTest: A Prospective Study Suggesting Reduction in Unnecessary MRI and Biopsy in Men Evaluated for Prostate Cancer. Cancers, 18(5), 871. https://doi.org/10.3390/cancers18050871

Vancouver

Rahbar K, Bögemann M, Papavasilis P, Halim A, Kidd M. Clinical Utility of PROSTest: A Prospective Study Suggesting Reduction in Unnecessary MRI and Biopsy in Men Evaluated for Prostate Cancer. Cancers. 2026;18(5):871. doi:10.3390/cancers18050871

BibTeX
@article{Rahbar2026,
  author = {Rahbar, Kambiz and Bögemann, Martin and Papavasilis, Philipp and Halim, Abdel and Kidd, Mark},
  title = {Clinical Utility of PROSTest: A Prospective Study Suggesting Reduction in Unnecessary MRI and Biopsy in Men Evaluated for Prostate Cancer},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {5},
  pages = {871},
  doi = {10.3390/cancers18050871}
}
Kostenlos starten →